elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q51636999-424B95BA-72CE-4BA2-AD8E-B3BD9E3E2572
Q51636999-424B95BA-72CE-4BA2-AD8E-B3BD9E3E2572
BestRank
Statement
http://www.wikidata.org/entity/statement/Q51636999-424B95BA-72CE-4BA2-AD8E-B3BD9E3E2572
A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.
P2860
Q51636999-424B95BA-72CE-4BA2-AD8E-B3BD9E3E2572
BestRank
Statement
http://www.wikidata.org/entity/statement/Q51636999-424B95BA-72CE-4BA2-AD8E-B3BD9E3E2572
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
924649bb2621068025563a55a9b6bf2d3902677c
P2860
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.